Article
Identification of HIF1A as a therapeutic target during SARS-CoV-2–associated lung injury
17 Jun 2025
Abstract excerpt
Hypoxia-inducible factors (HIFs) promote lung protection and pathogen eradication during acute lung injury. We, therefore, tested the theory that pharmacologic stabilization of HIFs dampens lung injury during SARS-CoV-2 pneumonia. Initial studies in murine SARS-CoV-2 models showed improved outcomes after treatment with the FDA-approved HIF stabilizer vadadustat. Subsequent studies in genetic models implicated...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
